Big Pharma, little science? A bibliometric perspective on big pharma's R&D decline. - Ismael Ràfols; Michael M. Hopkins; Jarno Hoekman; Josh Siepel; Alice O'Hare; Antonio Perianes-Rodríguez; Paul Nightingale (CoRR, 2013)

Just how difficult can it be counting up R&D funding for emerging technologies (and is tech mining with proxy measures going to be any better)? - Michael M. Hopkins; Josh Siepel (Technol. Anal. Strateg. Manag., 2013)

The spread of retracted research into policy literature. - Dmitry Malkov; Ohid Yaqub; Josh Siepel (Quant. Sci. Stud., 2023)